HGF and myeloid sarcoma: In Fig 1 the results from RR-MS are compared to those of the progressive MS patients: (HGF: 294±221 vs 484±310, p = 0.0002; Eotaxin/CCL11: 87±56 vs 187±143, p<0.0001; MCP-1/CCL2: 375±227 vs 588±309, p<0.0001; Rantes/CCL5: 4,173±4,855 vs 11,371±8,800, p<0.0001).